SUPN drops low-dose arm of pediatric-ADHD phase-3 trial following planned interim analysis: https://globenewswire.com/news-release/2017/09/18/1124316/0/en/Supernus-Provides-Update-on-SPN-810-Phase-III-Clinical-Trials.html CC at 5pm ET.